301126.SZ
Hunan Dajiaweikang Pharmaceutical Industry Co., Ltd.
SZSE · F 批发零售 · CN
CNY 10.00
−1.67%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 5.2B | 5.1B | 5.2B | 3.9B | 3.3B |
| Cost of Revenue | 4.3B | 4.2B | 4.2B | 3.3B | 2.9B |
| Gross Profit | 950.1M | 936.3M | 1.0B | 576.9M | 396.1M |
| Operating Expenses | |||||
| R&D Expense | 11.6M | 11.8M | 16.3M | 7.2M | 524.0K |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 183.0M | 180.5M | 166.9M | 102.4M | 77.1M |
| Selling & Marketing Expense | 657.6M | 646.6M | 658.1M | 321.8M | 179.6M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 987.0M | 978.5M | 970.3M | 519.0M | 306.8M |
| Cost and Expenses | 5.3B | 5.2B | 5.2B | 3.8B | 3.2B |
| Operating Income (EBIT) | (215.1M) | (216.2M) | 78.0M | 50.9M | 77.0M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (219.8M) | (220.4M) | 76.0M | 48.6M | 76.2M |
| Income Tax Expense | 9.3M | 8.3M | 24.7M | 10.5M | 20.9M |
| Bottom Line | |||||
| Net Income | (239.6M) | (242.5M) | 26.6M | 34.3M | 51.1M |
| Earnings from Cont. Ops | (229.1M) | (228.8M) | 51.3M | 38.0M | 55.3M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (239.6M) | (242.5M) | 26.6M | 34.3M | 51.1M |
| Per Share | |||||
| Basic EPS | (CN¥1.16) | (CN¥1.18) | CN¥0.13 | CN¥0.17 | CN¥0.25 |
| Diluted EPS | (CN¥1.16) | (CN¥1.18) | CN¥0.13 | CN¥0.17 | CN¥0.25 |
| Revenue Per Share | CN¥26.30 | CN¥25.04 | CN¥25.60 | CN¥19.35 | CN¥16.11 |
| Shares | |||||
| Basic Shares Outstanding | 198.8M | 205.5M | 204.4M | 201.8M | 204.3M |
| Diluted Shares Outstanding | 198.8M | 205.5M | 204.4M | 201.8M | 204.3M |
| Profitability Metrics | |||||
| EBITDA | — | (134.1M) | 151.3M | 150.5M | 108.7M |
| D&A | — | 82.0M | 73.4M | 99.6M | 31.7M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026